All > North Carolina > Maryland

IMGN632 for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute Myeloid Leukemia+3 MoreIMGN632 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a new drug, IMGN632, to see if it is safe and effective in treating patients with blood cancer.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Myeloproliferative Neoplasms
  • Acute Lymphoblastic Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Arm I (tranexamic acid)
1
Radiation Therapy
1
LY3541105

Study Objectives

1 Primary · 11 Secondary · Reporting Duration: Up to 24 months

21-day cycle
To assess the rate of composite CR in BPDCN patients
Up to 24 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
To assess ORR: CR+CRc+CRh+CRi+PR
To assess OS
To assess the duration of CR (DOCR) for patients with CR or CRc
Corticotropin-releasing hormone
To assess the duration of overall response
To assess the percent of BPDCN patients able to bridge to stem cell transplant in the frontline and relapsed/refractory populations separately
To assess the rate of CR+CRc+CRh
To assess transfusion independence
To characterize the PK of IMGN632, total antibody, and FGN849 (the active catabolite)
To evaluate the potential immunogenicity of IMGN632

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Arm I (tranexamic acid)
1
Radiation Therapy
1
LY3541105

Trial Design

1 Treatment Group

Escalation and Expansion
1 of 1

Experimental Treatment

252 Total Participants · 1 Treatment Group

Primary Treatment: IMGN632 · No Placebo Group · Phase 1 & 2

Escalation and Expansion
Drug
Experimental Group · 1 Intervention: IMGN632 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

ImmunoGen, Inc.Lead Sponsor
29 Previous Clinical Trials
3,748 Total Patients Enrolled
Patrick Zweidler-McKay, MDStudy DirectorImmunoGen, Inc.
2 Previous Clinical Trials
336 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not received prior CD123-targeting agents.
Patients with relapsed or refractory BPDCN with 1-3 prior lines of therapy.
Patients with frontline BPDCN who have not received prior systemic therapy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top